Weekly channel feed – Endpoints News

Weekly channel feed

Trump announces picks for FDA, CDC; Novartis seeks bolt-on deals, raises guidance; RFK Jr., Elon Musk may find banning ads difficult; and more

6 months ago

Trump picks RFK Jr. for HHS; AbbVie's psych implosion; Merck tries staving off Summit; and more

6 months ago

How Trump, RFK Jr. could influence biopharma; Viking presents weight loss data; Are MASH drugs getting boxed out by GLP-1s?; and more

6 months ago

How RFK Jr. might influence the FDA; Pharma's Q3 highlights; AbbVie's latest neuro buyout; and more

6 months ago

Latest salvo in Pfizer activist fight; John Carroll's Q3 biotech roundup; Intellia unveils CRISPR results; and more

7 months ago

A Q&A with a Nobel Prize winner; Pfizer meets with Starboard; J&J reports Q3 earnings; and more

7 months ago

Pfizer's situation with Starboard; Meet Endpoints' 2024 Women in Biopharma; Nobel Prizes highlight AI era

7 months ago

WuXi companies consider sale of units impacted by Biosecure; J&J, Bayer trim staff; Ron Renaud’s latest biotech; and more

7 months ago

Meet this year’s Endpoints 11; J&J winds down cardiovascular and metabolic unit; BMS wins schizophrenia approval; and more

7 months ago

John Carroll on his cancer diagnosis; #ESMO's biggest surprise; Lykos' bad trip; Rate cuts, and more

8 months ago

House passes Biosecure Act; Moderna outlines more cost cuts; What's happening at #ESMO24; and more

8 months ago

Notable shakeups this week; Recursion's mixed data; Eli Lilly's $1B bet; and more

8 months ago

FDA authorizes Novavax Covid booster; Recursion nears key data readouts; What’s next for CD47?; and more

8 months ago

Tome plans layoffs amid struggle; FDA turns away Regeneron; Next-gen obesity startup launches; James Sabry joins BioMarin; and more

9 months ago

Unpacking IRA price negotiations results; Lykos’ tough week; Genentech rethinks cancer immunology; and more

9 months ago

Latest on MDMA rejection; Novo vs. Lilly earnings; Recursion, Exscientia to merge; Q&A with Genentech CEO; and more

9 months ago

Eisai’s new Leqembi data; Jim Wilson’s next move; Roivant dealmaker’s payday; What’s next for MDMA?; and more

9 months ago

Mapping GLP-1 game plans; Q2 earnings highlights; J&J vets regroup at startup; and more

10 months ago

A rare disease first; Lilly’s Alzheimer’s push; Argenx’s next act; Novartis' obesity approach; and more

10 months ago

Deep dive on pay packages; Lilly strikes $3.2B buyout; Pfizer’s R&D head to depart; and more

10 months ago

Eli Lilly’s Alzheimer’s OK; GSK picks its mRNA bets; Megaround tally; Biosecure's shadow; and more

10 months ago

Alnylam's big Phase 3 win; LGBTQ+ leaders charting paths; Chevron overturned; and more

11 months ago

Sarepta's big gene therapy expansion; Inside Iambic's AI cycle; Vertex, Lilly unveil new diabetes data; and more

11 months ago

BIO CEO’s patriotic pivot; Step forward for Lilly’s Alzheimer’s drug; Pfizer’s gene therapy setback; Foresite’s $900M fund

11 months ago

First page Previous page 123 4 5 Next page Last page